Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | M237I |
Impact List | missense |
Protein Effect | loss of function |
Gene Variant Descriptions | TP53 M237I lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). M237I results in decreased DNA binding and Tp53 transactivation activity, resistance to apoptosis, failure of G1 arrest in cell culture (PMID: 16492679, PMID: 20080630, PMID: 31395785), increased colony formation compared to wild-type in the presence of an MDM2 antagonist in cell culture, and tumor growth in mouse models (PMID: 35165384). |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 exon7 TP53 M237I TP53 mutant TP53 inact mut TP53 M237I |
Transcript | NM_000546.6 |
gDNA | chr17:g.7674252C>G |
cDNA | c.711G>C |
Protein | p.M237I |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001126113.3 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_000546.5 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_001407270.1 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_001126112.3 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_001126114.3 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_001407266.1 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_001126112.2 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_001407264.1 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_000546 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_000546.6 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_001126113 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_001126114.2 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_001126114 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_001126113.2 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_001126112 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_001407262.1 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
NM_001407268.1 | chr17:g.7674252C>G | c.711G>C | p.M237I | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 M237I | high grade glioma | sensitive | AZ32 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, AZ32 treatment increased sensitivity to radiotherapy in malignant glioma cells harboring TP53 M237I in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 29769307). | 29769307 |
TP53 M237I | high grade glioma | sensitive | KU-60019 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, KU-60019 treatment increased sensitivity to radiotherapy in malignant glioma cells harboring TP53 M237I in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 29769307). | 29769307 |